Status:

COMPLETED

Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions:

Depressive Disorder, Major

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder. Additional objectives include testing bot...

Eligibility Criteria

Inclusion

  • A primary diagnosis of MDD
  • Depressive symptoms for at least 30 days before the screening visit.

Exclusion

  • Treatment with DVS SR at any time in the past.
  • Known hypersensitivity to venlafaxine
  • Significant risk of suicide based on clinical judgment

Key Trial Info

Start Date :

March 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2007

Estimated Enrollment :

480 Patients enrolled

Trial Details

Trial ID

NCT00300378

Start Date

March 1 2006

End Date

January 1 2007

Last Update

December 5 2007

Active Locations (43)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (43 locations)

1

Rijeka, Croatia, 51000

2

Split, Croatia, 21000

3

Zagreb, Croatia, 10090

4

Tallinn, Estonia, 126 18